title: One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration.
abstract: OBJECTIVE
  We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD).
  
  
  METHODS
  Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared.
  
  
  RESULTS
  VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01).
  
  
  CONCLUSIONS
  Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections.
authors.affiliation: Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Takayama
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kaneko
authors.forename: Tadasu
authors.initials: T
authors.lastname: Sugita
authors.forename: Ruka
authors.initials: R
authors.lastname: Maruko
authors.forename: Kyoko
authors.initials: K
authors.lastname: Hattori
authors.forename: Eimei
authors.initials: E
authors.lastname: Ra
authors.forename: Kenichi
authors.initials: K
authors.lastname: Kawano
authors.forename: Keiko
authors.initials: K
authors.lastname: Kataoka
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Ito
authors.forename: Hiroko
authors.initials: H
authors.lastname: Terasaki
mesh_terms: D000368:Aged; D020256:Choroidal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012160:Retina / Q000000981:diagnostic imaging*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor